Christoph Zielinski
YOU?
Author Swipe
View article: 11th Immunotherapy of Cancer conference (ITOC): A meeting report
11th Immunotherapy of Cancer conference (ITOC): A meeting report Open
The Immunotherapy of Cancer (ITOC) meeting is an international conference providing a platform for immuno-oncologists worldwide to present and discuss their research and newest findings. Being held in Munich annually, the 11th edition took…
View article: Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Open
PURPOSE For hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard of car…
View article: ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) Open
View article: Supplementary Figure S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 1. Survival analysis in baseline population (C1D1).
View article: Supplementary Table S12 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S12 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 12. Baseline genomic landscape of mutations distribution for the CDR population (n=120), by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Table S11 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S11 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 11. Baseline characteristics comparison between population with CDR calculation (n=120) vs non-CDR population (n=81).
View article: Supplementary Table S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 1. List of the 21 genes included in the breast cancer panel used for sequencing, and the targeted coding regions in each case.
View article: Supplementary Table S9 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S9 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
View article: Supplementary Figure S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 2. PFS analysis in baseline population (C1D1) on TP53 mutations, by treatment arms.
View article: Supplementary Figure S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 5. CDR and clinical benefit rate within the longitudinal predictive ctDNA analysis.
View article: Supplementary Table S12 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S12 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 12. Baseline genomic landscape of mutations distribution for the CDR population (n=120), by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Figure S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 3. Survival analysis in baseline population (C1D1) on TP53 mutations, within the population with any detectable mutation (n=146).
View article: Supplementary Figure S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 3. Survival analysis in baseline population (C1D1) on TP53 mutations, within the population with any detectable mutation (n=146).
View article: Supplementary Table S6 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S6 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 6. Summary of all baseline mutations identified for the 146 patients with ctDNA detection.
View article: Supplementary Table S7 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S7 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 7. Baseline genomic landscape of mutations distribution in population, by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Table S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S1 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 1. List of the 21 genes included in the breast cancer panel used for sequencing, and the targeted coding regions in each case.
View article: Supplementary Table S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S3 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 3. Complete table results for all patients (n=120) involved in C1D15 analysis.
View article: Supplementary Figure S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 5. CDR and clinical benefit rate within the longitudinal predictive ctDNA analysis.
View article: Data from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Data from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Purpose: Prognostic and predictive biomarkers to CDK4/6 inhibitors are lacking. Circulating tumour DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we c…
View article: Supplementary Figure S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).
View article: Supplementary Table S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 5. Baseline characteristics comparison between treatment arms in the selected study population
View article: Supplementary Table S10 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S10 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 10. Summary of OS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
View article: Supplementary Table S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 4. Baseline characteristics comparison between our selected study population and the overall PEARL population.
View article: Supplementary Table S9 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S9 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
View article: Supplementary Figure S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 2. PFS analysis in baseline population (C1D1) on TP53 mutations, by treatment arms.
View article: Supplementary Table S7 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S7 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 7. Baseline genomic landscape of mutations distribution in population, by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Figure S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Figure S4 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).
View article: Supplementary Table S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S2 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 2. Complete table results for all patients (n=201) involved in baseline (C1D1) analysis.
View article: Supplementary Table S8 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S8 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 8. Summary of baseline ESR1 and PIK3CA mutations, with number of affected patients and mean VAF.
View article: Supplementary Table S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients
Supplementary Table S5 from Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients Open
Supplementary Table 5. Baseline characteristics comparison between treatment arms in the selected study population